|
|
Prepublished online as a Blood First Edition Paper on October 17, 2002; DOI 10.1182/blood-2002-08-2441.
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2003, Vol. 101, No. 5, pp. 1715-1717
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
Prognostic value of angiogenesis in solitary bone
plasmacytoma
Shaji Kumar,
Rafael Fonseca,
Angela Dispenzieri,
Martha Q. Lacy,
John A. Lust,
Linda Wellik,
Thomas E. Witzig,
Morie A. Gertz,
Robert A. Kyle,
Philip R. Greipp, and
S. Vincent Rajkumar
From the Division of Hematology and Internal Medicine,
Mayo Clinic, Rochester, MN.
Angiogenesis plays an important role in the biology of
multiple myeloma (MM) and has prognostic importance in this disease. Solitary plasmacytoma is a localized plasma cell malignancy that progresses to MM in a significant number of patients. We examined if
angiogenesis is increased in solitary plasmacytoma and if it can help
identify patients likely to progress to myeloma. We studied angiogenesis in plasmacytoma biopsy samples and bone marrow
biopsies from 25 patients. High-grade angiogenesis was present in 64%
of plasmacytomas. In contrast, bone marrow angiogenesis was low in all
patients. Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myeloma and had a shorter progression-free survival compared with patients with low-grade angiogenesis (P = .02). Angiogenesis is increased in
solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Dingli, R. A. Kyle, S. V. Rajkumar, G. S. Nowakowski, D. R. Larson, J. P. Bida, M. A. Gertz, T. M. Therneau, L. J. Melton III, A. Dispenzieri, et al.
Immunoglobulin free light chains and solitary plasmacytoma of bone
Blood,
September 15, 2006;
108(6):
1979 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle
Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
May 1, 2006;
81(5):
693 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Hematology,
January 1, 2005;
2005(1):
340 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. E. Witzig, M. Timm, J. Haug, L. Wellik, T. K. Kimlinger, P. R. Greipp, and S. V. Rajkumar
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Blood,
August 15, 2004;
104(4):
1159 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
Blood,
April 15, 2004;
103(8):
3131 - 3137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
